Hematologic Malignancy

Original Article

High-risk extranodal natural killer/T-cell lymphoma patients could benefit more from allogeneic hematopoietic stem cell transplantation as consolidation: A real-world multicenter analysis in China
Yuewen Wang,Yi Xia,Zhenyang Gu,Yu Chang,Lei Yang,Peipei Yang,Yanmin Zhao,Chunli Zhang,Na Wang,Shenmiao Yang,Yang Yang,Chuanhe Jiang,Leqing Cao,Daoxing Deng,Haiyang Lu,Fengrong Wang,Mingzhi Zhang,Yang Cao,Xiaoxia Hu,Ting Niu,Xiaodong Mo
Can one scoring system fit all? Comparative validation of CAR-HEMATOTOX, ALL-HEMATOTOX, and eIPM for predicting immune effector cell-associated hematotoxicity following CAR-T therapy in hematologic malignancies
Aoran Zhang,Hao Zheng,Qiannan Shang,Xianying Yin,Yihan Yang,Ya Luo,Tong Su,Xuelin Dou,Ting Zhao,Xuying Pei,Zhuojun Liu,Jin Lu,Xiaohui Zhang,Xiaojun Huang,Xiaodong Mo,Meng Lv,Xiangyu Zhao
Impact of clinical characteristics and genetic profiles on outcomes of allogeneic stem cell transplantation with sorafenib maintenance in FLT3-ITD acute myeloid leukemia patients: A multi-center, retrospective study
Yeqian Zhao,Chuanhe Jiang,Yi Luo,Guifang Ouyang,Lieguang Chen,Jian Yu,Yamin Tan,Xiaoyu Lai,Lizhen Liu,Huarui Fu,Yishan Ye,Luxin Yang,Congxiao Zhang,Jimin Shi,He Huang,Xiaoxia Hu,Yanmin Zhao
Prognostic value of post-transplantation measurable residual disease in patients with myelodysplastic syndrome: A prospective cohort study
Yuewen Wang,Lanping Xu,Yu Wang,Xiaohui Zhang,Kaiyan Liu,Yuanyuan Zhang,Chenhua Yan,Huan Chen,Yuhong Chen,Wei Han,Fengrong Wang,Jingzhi Wang,Xiaojun Huang,Yingjun Chang
Venetoclax and azacitidine compared with intensive chemotherapy for adverse-risk acute myeloid leukemia patients receiving allogeneic hematopoietic stem cell transplantation in first complete remission: A multicenter study of TROPHY group
Qi Wen,Chuanhe Jiang,Xiaodan Liu,Yi Xia,Yilei Ma,Yang Yang,Yu Wang,Yingjun Chang,Luxiang Wang,Zilu Zhang,Xiaojun Huang,Yang Cao,Yanmin Zhao,Xiaoxia Hu,Xiaodong Mo
Quality-adjusted time without symptoms or toxicity analysis of haploidentical-related donor vs. identical sibling donor hematopoietic stem cell transplantation in acute myeloid leukemia
Yuewen Wang,Xianli Gao,Ting Wang,Xiaohui Zhang,Lanping Xu,Yu Wang,Chenhua Yan,Huan Chen,Yuhong Chen,Wei Han,Fengrong Wang,Jingzhi Wang,Xia Yan,Xiaodong Mo,Xiaojun Huang

Perspective

Allogeneic transplantation in adverse-risk acute myeloid leukemia: Challenges, strategies, and future directions
Jingtao Huang,Xinyi Wu,Gaoxiang Wang,Yang Cao,Xiaoxia Hu,on behalf of TROPHY working group

Correspondence

Haploidentical donor vs. human leukocyte antigen-matched donor hematopoietic cell transplantation for elderly patients with hematologic malignancies: Inferior non-relapse mortality but comparable survival
Mengqi Xiang,Xiang Zhang,Mimi Xu,Yuqing Tu,Juan Shen,Xiaoli Li,Xiaojin Wu,Suning Chen,Ying Wang,Yue Han,Miao Miao,Aining Sun,Huiying Qiu,Yi Fan,Depei Wu,Jia Chen
Outcomes of adult patients with B-cell acute lymphoblastic leukemia with or without blinatumomab as bridging therapy prior to allogeneic hematopoietic stem cell transplantation
Jiayu Huang,Yi Xia,Yuhang Cheng,Bingyang Shi,Yilei Ma,Ze Tian,Luxiang Wang,Chuanhe Jiang,Haiyang Lu,Weijie Cao,Yang Cao,Xiaodong Mo,Xiaoxia Hu